Search Results for: ustr

Abbott sought compulsory license in 2007 US patent dispute

Sunday, 29 April 2007

(When the shoe was on the other foot, Abbott asked for a compulsory license, while criticizing Thailand for issuing compulsory licenses)
 

On the 12th of January 2007, Abbott Laboratories lost a bid in a U.S. District Court (the Western District of Wisconsin) for a compulsory license on a patent held by Innogenetics, Inc. that a judge and jury said Abbott infringed to manufacture and sell Hepatitis C virus (HCV) genotyping test kits.

 

Continue Reading →

Novartis (NVS): Some Examples of Joint Ventures, Partnerships, and Alliances

Wednesday, 29 August 2007

According to the Novartis strategic alliances webpage, the company is engaged in "More than 400 collaborations in over 20 countries, over 120 collaborations with major biotech companies, and over 280 collaborations with academic centers."

Selected Joint Ventures, Partnerships, and Alliances with Big Pharma 

Novartis and Bayer Schering AG  – PTK/ZK – These two companies initially collaborated in the devel Continue Reading →

Merck & Co., Inc. (MRK): Select Joint Ventures, Partnerships, and Alliances

Friday, 07 September 2007

According to the Merck licensing and partnership website, "Eleven of our 20 new products launched since 1995 are the result of licensing alliances."  The site lists Merck's partners, which include small and medium-sized pharma, universities, and biotech firms, but none of their big pharma competitors.

Select Joint Ventures, Partnerships, and Alliances with Small and Midsized Pharma Continue Reading →

Abbott (ABT): Select Joint Ventures, Partnerships, and Alliances

Monday, 10 September 2007

Select Joint Ventures, Partnerships, and Alliances with Big Pharma

Abbott and Millennium – In March 2001 Abbott and Millennium formed a strategic alliance for the discovery, development and commercialization of drugs and diagnostics in the area of obesity and diabetes.  This alliance also provided for non-exclusive technology transfer and the co-development of technology tools.  According to Millennium's 2001 SEC filing, the deal i Continue Reading →

KEI Achievements

$1 a day HIV/AIDS drug regimen
In the early 2000s, KEI’s founder, James Love, advocated to lower the price of HIV/AIDS drugs for patients in developing countries. Love convinced generic manufacturer Cipla to sell the standard 3-drug HIV/AIDS regimen for $1 per day, a breakthrough price that saved — and continues to save — millions of lives. Love’s work culminated in the creation of the Global Fund for HIV/AIDS, TB and Malaria and the President’s Emergency Plan For AIDS Relief (PEPFAR), two of the world’s largest providers of HIV/AIDS treatments.

Continue Reading →

Sept 10, 2009 KEI brownbag lunch on Bilski litigation

KEI will host a meeting on the Bilski litigation regarding patents on business methods, on September 10, 2009, from noon to 2:00.

When: Thursday, September 10, 2009
Time: 12:00-2:00pm
Location:
Knowledge Ecology International (KEI)
1621 Connecticut Ave NW, Suite 500
Washington, DC 20009
Tel +1 202 332 2670

The meeting will include presentations by:

Continue Reading →